<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We reported 37 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) of refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath> or <z:hpo ids='HP_0005505'>refractory anemia</z:hpo> with excess blasts who were treated with <z:chebi fb="0" ids="4031">cyclosporin A</z:chebi> (CyA)/thalidomide combination therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Of them, 19 patients (19/37, 51.4%) achieved a hematologic improvement and erythroid response (HI-E); 9 patients (9/29, 31.0%) achieved hematologic improvement and platelet response (HI-P) and 7 patients (7/33, 21.2%) achieved hematologic improvement and neutrophil response (HI-N) </plain></SENT>
<SENT sid="2" pm="."><plain>15 of 32 (46.9%) transfusion-dependent patients achieved independence from transfusion </plain></SENT>
<SENT sid="3" pm="."><plain>The median response duration of HI-E, HI-P and HI-N were 88 (4-108) weeks, 78 (8-84+) weeks and 78 (10-84+) weeks, respectively </plain></SENT>
<SENT sid="4" pm="."><plain>Some patients presented with I or II grade hepatic or nephritic impairment, <z:hpo ids='HP_0002019'>constipation</z:hpo>, <z:hpo ids='HP_0001254'>lethargy</z:hpo>, dizziness, <z:hpo ids='HP_0000969'>edema</z:hpo>, <z:e sem="disease" ids="C0015230" disease_type="Disease or Syndrome" abbrv="">rash</z:e> or sense of numbness </plain></SENT>
<SENT sid="5" pm="."><plain>Therefore, CyA combined with thalidomide appears to be useful and is relatively well-tolerated for patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>